Cerus Director Sells $53,180 in Stock at $3.74
1h ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
cerus-corpinsider-tradinghealthcare-stocks
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
Eric Bjerkholt, a director of Cerus Corporation, sold 14,219 shares of the company's common stock at a price of $3.74 per share on June 5. The transaction, disclosed in a regulatory filing on June 11, resulted in proceeds of approximately $53,180. The Form 4 filing with the U.S. Securities and Exchange Commission shows the sale was executed under a pre-arranged 10b5-1 trading plan. Cerus Corp, which trades on the NASDAQ under the ticker CERS, develops and commercializes the INTERCEPT Blood System for blood safety.
Insider sales by directors at Cerus are infrequent but not unprecedented. On February 14, 2024, another Cerus director, Mohandas Moses, sold 13,000 shares at $2.31 per share, a transaction valued at roughly $30,000. Prior to that, in August 2023, a different director sold approximately $65,000 worth of shares.
The current trade occurs as Cerus stock trades near its 52-week high of $3.90, having gained over 40% year-to-date. This recent strength follows a period of elevated volatility tied to the company's quarterly earnings reports and pipeline updates for its pathogen reduction technology.
The trigger for this specific transaction appears to be the activation of a pre-set 10b5-1 plan. These plans allow company insiders to schedule sales in advance to avoid accusations of trading on non-public information. The sale's execution near a recent high suggests the plan's price parameters were met.
The sale of 14,219 shares reduced Bjerkholt's direct holdings in Cerus to 79,716 shares. At the $3.74 sale price, his remaining stake is valued at approximately $298,000. Cerus Corporation has a market capitalization of $685 million based on its current share price and 183 million shares outstanding.
The transaction price of $3.74 represents a premium to the stock's 200-day simple moving average of $2.56. Year-to-date, CERS shares are up 41.5%, significantly outperforming the iShares Biotechnology ETF (IBB), which is up 6.2% over the same period.
The table below shows a before-and-after comparison of the director's share ownership:
| Metric | Before Sale | After Sale |
|---|---|---|
| Shares Held | 93,935 | 79,716 |
| Notional Value at $3.74 | ~$351,000 | ~$298,000 |
Peer company Haemonetics (HAE), which operates in the blood management and plasma collection sectors, trades at a forward price-to-earnings ratio of 22x. Cerus is not yet profitable on a net income basis.
This sale has limited direct market impact, representing roughly 0.008% of Cerus's outstanding float. The magnitude is typical for routine portfolio management by a non-executive director. It does not signal a major shift in insider sentiment across the broader biotechnology sector.
The trade's second-order effect may be a subtle increase in selling pressure for small-cap healthcare stocks, particularly those with thin liquidity like Cerus. Algorithmic trading systems monitoring SEC filings may parse this as a minor negative signal, potentially leading to short-term underperformance relative to peers like CSL Behring parent CSL Limited or Grifols.
A key counter-argument is that sales under 10b5-1 plans are scheduled and non-discretionary, diminishing their informational value about a director's current outlook. The remaining $298,000 stake also indicates maintained economic exposure. Flow data suggests institutional investors have been net buyers of CERS over the past quarter, while retail sentiment on social trading platforms has been mixed.
The next major catalyst for Cerus is its second-quarter 2024 earnings report, scheduled for late July or early August. Analysts will focus on INTERCEPT system sales growth in the U.S. and European markets, which were $39.5 million in Q1.
Investors should watch the $3.50 level, which has acted as recent support. A sustained break below this could target the 50-day moving average near $3.15. Resistance sits at the 52-week high of $3.90.
Regulatory updates from the U.S. Food and Drug Administration or other health agencies regarding pathogen-reduced blood products represent another potential catalyst. Positive news could benefit the entire blood safety sub-sector, including smaller players like Terumo Blood and Cell Technologies.
A 10b5-1 plan is a pre-arranged, written trading plan established by a company insider when they are not in possession of material non-public information. It allows for automatic trades at future dates or specific price points. This mechanism provides an affirmative defense against accusations of insider trading, as trades are executed according to the pre-set formula regardless of subsequent news.
For a company with Cerus's $685 million market cap, a $53,000 sale is a very small transaction, representing a tiny fraction of daily trading volume. It is more indicative of routine personal financial planning, such as tax payments or portfolio diversification, than a negative view on the company's prospects. The director retained over 79,000 shares, demonstrating continued alignment with shareholders.
Cerus operates in a niche within the broader plasma protein and blood safety market. Unlike profitable larger peers like CSL or Grifols, Cerus is focused on growth and has not yet achieved consistent net profitability. Its valuation is primarily driven by sales growth for its INTERCEPT system and its potential to gain market share in pathogen reduction, a specialized segment with high regulatory barriers.
A Cerus director's scheduled stock sale is a minor liquidity event that does not alter the company's commercial growth narrative.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.